Institut Pasteur

Centre National De La Recherche Scientifique

Institut Pasteur and Centre National De La Recherche Scientifique

Francedillaois Clavel

Luc Montagnier

Pierre Sonigo

Marc Alizon

Denise Guetard

Mireille Guyader

Solange Chamaret

Bernard Krust

Simon Wain-Hobson

Stewart T Cole

Jean-Claude Chermann

Christine Rouzioux

Christine Katlama

Marianne Rey

Olivier Danos

Francedillaoise Barre-Sinoussi

Francedillaoise Brun-Vezinet

Francedillaoise Rey

Methods for producing the newly discovered HIV-2 retrovirus and its antigens are provided. The antigens are obtained from various HIV-2 retroviruses. The antigen compositions comprise a lysate of an HIV-2 retrovirus, a protein of an HIV-2 retrovirus, or a glycoprotein of an HIV-2 retrovirus. Specifically, the antigen composition can comprise p12, p16, p26, gp32, gp42, and gp140.

Methods for the preparation of human immunodeficiency virus type 2

This invention is directed to nucleic acids derived from the pol region of the genome of human immunodeficiency virus type 1 (HIV-1). The nucleic acids are useful as probes for the detection of HIV-1. More particularly, this invention is directed to nucleic acids encoding a pol region of HIV-1 extending from about nucleotide 1856 to about 1906 and extending from about nucleotide 2048 to about nucleotide 2797.

Nucleic acids and pepties of human immunodeficiency virus type-1 (HIV-1).

The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.

In vitro diagnostic assays for the detection of HIV-1 or HIV-2 employing

The invention relates to new purified antigens of the LAV virus. They have molecular weights of about 135,000 and 150,000 daltons. They are useful for the detection of LAV antibodies in human sera. They are produced by hybrid cell-lines resulting from the fusion of T4 lymphocytes and cells of the MOLT-4 cell line.

Hybrid cell line formed between T4 lymphocytes and tumoral lymphoid type

Growing community of inventors

Paris, France

Francedillaois Clavel